http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Georgakilas, Vasilios,Tiwari, Jitendra N.,Kemp, K. Christian,Perman, Jason A.,Bourlinos, Athanasios B.,Kim, Kwang S.,Zboril, Radek American Chemical Society 2016 Chemical reviews Vol.116 No.9
<P>This Review focuses on noncovalent functionalization of graphene and graphene oxide with various species involving biomolecules, polymers, drugs, metals and metal oxide-based nanoparticles, quantum dots, magnetic nanostructures, other carbon allotropes (fullerenes, nanodiamonds, and carbon nanotubes), and graphene analogues (MoS2, WS2). A brief description of pi-pi interactions, van der Waals forces, ionic interactions, and hydrogen bonding allowing noncovalent modification of graphene and graphene oxide is first given. The main part of this Review is devoted, to tailored functionalization for applications in drug delivery, energy materials, solar cells, water splitting, biosensing, bioimaging, environmental, catalytic, photocatalytic, and biomedical technologies. A significant part of this Review explores the possibilities of graphene/graphene oxide-based 3D superstructures and their use in lithium-ion batteries. This Review ends with a look at challenges and future prospects of noncovalently modified graphene and graphene oxide.</P>
Functionalization of Graphene: Covalent and Non-Covalent Approaches, Derivatives and Applications
Georgakilas, Vasilios,Otyepka, Michal,Bourlinos, Athanasios B.,Chandra, Vimlesh,Kim, Namdong,Kemp, K. Christian,Hobza, Pavel,Zboril, Radek,Kim, Kwang S. American Chemical Society 2012 Chemical reviews Vol.112 No.11
<P><B>Graphic Abstract</B> <IMG SRC='http://pubs.acs.org/appl/literatum/publisher/achs/journals/content/chreay/2012/chreay.2012.112.issue-11/cr3000412/production/images/medium/cr-2012-000412_0001.gif'></P>
Amin, A.R.M.R.,Karpowicz, P.A.,Carey, T.E.,Arbiser, J.,Nahta, R.,Chen, Z.G.,Dong, J.T.,Kucuk, O.,Khan, G.N.,Huang, G.S.,Mi, S.,Lee, H.Y.,Reichrath, J.,Honoki, K.,Georgakilas, A.G.,Amedei, A.,Amin, A. Saunders Scientific Publications ; Academic Press 2015 SEMINARS IN CANCER BIOLOGY Vol.35 No.suppl
The evasion of anti-growth signaling is an important characteristic of cancer cells. In order to continue to proliferate, cancer cells must somehow uncouple themselves from the many signals that exist to slow down cell growth. Here, we define the anti-growth signaling process, and review several important pathways involved in growth signaling: p53, phosphatase and tensin homolog (PTEN), retinoblastoma protein (Rb), Hippo, growth differentiation factor 15 (GDF15), AT-rich interactive domain 1A (ARID1A), Notch, insulin-like growth factor (IGF), and Kruppel-like factor 5 (KLF5) pathways. Aberrations in these processes in cancer cells involve mutations and thus the suppression of genes that prevent growth, as well as mutation and activation of genes involved in driving cell growth. Using these pathways as examples, we prioritize molecular targets that might be leveraged to promote anti-growth signaling in cancer cells. Interestingly, naturally occurring phytochemicals found in human diets (either singly or as mixtures) may promote anti-growth signaling, and do so without the potentially adverse effects associated with synthetic chemicals. We review examples of naturally occurring phytochemicals that may be applied to prevent cancer by antagonizing growth signaling, and propose one phytochemical for each pathway. These are: epigallocatechin-3-gallate (EGCG) for the Rb pathway, luteolin for p53, curcumin for PTEN, porphyrins for Hippo, genistein for GDF15, resveratrol for ARID1A, withaferin A for Notch and diguelin for the IGF1-receptor pathway. The coordination of anti-growth signaling and natural compound studies will provide insight into the future application of these compounds in the clinical setting.
Immune evasion in cancer: Mechanistic basis and therapeutic strategies
Vinay, D.S.,Ryan, E.P.,Pawelec, G.,Talib, W.H.,Stagg, J.,Elkord, E.,Lichtor, T.,Decker, W.K.,Whelan, R.L.,Kumara, H.M.C.S.,Signori, E.,Honoki, K.,Georgakilas, A.G.,Amin, A.,Helferich, W.G.,Boosani, C. Saunders Scientific Publications ; Academic Press 2015 SEMINARS IN CANCER BIOLOGY Vol.35 No.suppl
Cancer immune evasion is a major stumbling block in designing effective anticancer therapeutic strategies. Although considerable progress has been made in understanding how cancers evade destructive immunity, measures to counteract tumor escape have not kept pace. There are a number of factors that contribute to tumor persistence despite having a normal host immune system. Immune editing is one of the key aspects why tumors evade surveillance causing the tumors to lie dormant in patients for years through ''equilibrium'' and ''senescence'' before re-emerging. In addition, tumors exploit several immunological processes such as targeting the regulatory T cell function or their secretions, antigen presentation, modifying the production of immune suppressive mediators, tolerance and immune deviation. Besides these, tumor heterogeneity and metastasis also play a critical role in tumor growth. A number of potential targets like promoting Th1, NK cell, γδ T cell responses, inhibiting Treg functionality, induction of IL-12, use of drugs including phytochemicals have been designed to counter tumor progression with much success. Some natural agents and phytochemicals merit further study. For example, use of certain key polysaccharide components from mushrooms and plants have shown to possess therapeutic impact on tumor-imposed genetic instability, anti-growth signaling, replicative immortality, dysregulated metabolism etc. In this review, we will discuss the advances made toward understanding the basis of cancer immune evasion and summarize the efficacy of various therapeutic measures and targets that have been developed or are being investigated to enhance tumor rejection.